PDF(Pubmed)
Abstract：
UNASSIGNED: Remimazolam is a novel short-acting benzodiazepine used for sedation and general anesthesia. This study aimed to evaluate the efficacy and safety of remimazolam besylate in elderly patients who underwent diagnostic gastrointestinal endoscopy.
UNASSIGNED: A total of 120 patients aged 60-75 years were randomly allocated to one of two groups. Remifentanil 0.3μg/kg was used for analgesia. Patients were administered remimazolam besylate 7 mg (R group) or etomidate 0.1 mg/kg combined with 1% propofol 0.5 mg/kg (EP group) for induction, supplemental repeated doses were given as needed. Some time metrics, vital signs, adverse events were evaluated. Patients\' Mini-cog score and recovery questionnaires were compared.
UNASSIGNED: Compared to the EP group, the induction time was slightly longer in the R group (1.50 VS 1.15 minutes) (P<0.05), the time spent in the post-anesthesia care unit (PACU) was shorter (15.17 VS 17.40 minutes) (P<0.05). Compare with EP group, SBP was lower in R group at T15 and T25 time point, but heart rate was higher in T2, T3, T5 (P< 0.05). The Mini-Cog score was higher after the procedure (2.83 VS 2.58) (P<0.05). The incidence of respiratory adverse events was higher in the EP group than R group (18.3% VS 5.0%, P < 0.05). The most common adverse event in R group was hiccups. The sedation satisfaction rate and degree of amnesia were higher in the R group (66.7% VS 11.7%) (P < 0.05), and the effect on patient\'s life within 24 hours was lower (12.0% VS 30.5%) (P < 0.05).
UNASSIGNED: The safety and efficacy of remimazolam besylate are not inferior to those of etomidate combined with propofol, rendering it a safe option for sedation during gastrointestinal endoscopy in ASA I-II elderly patients, but care should be taken to monitor the occurrence of hiccups.
UNASSIGNED: A total of 120 patients aged 60-75 years were randomly allocated to one of two groups. Remifentanil 0.3μg/kg was used for analgesia. Patients were administered remimazolam besylate 7 mg (R group) or etomidate 0.1 mg/kg combined with 1% propofol 0.5 mg/kg (EP group) for induction, supplemental repeated doses were given as needed. Some time metrics, vital signs, adverse events were evaluated. Patients\' Mini-cog score and recovery questionnaires were compared.
UNASSIGNED: Compared to the EP group, the induction time was slightly longer in the R group (1.50 VS 1.15 minutes) (P<0.05), the time spent in the post-anesthesia care unit (PACU) was shorter (15.17 VS 17.40 minutes) (P<0.05). Compare with EP group, SBP was lower in R group at T15 and T25 time point, but heart rate was higher in T2, T3, T5 (P< 0.05). The Mini-Cog score was higher after the procedure (2.83 VS 2.58) (P<0.05). The incidence of respiratory adverse events was higher in the EP group than R group (18.3% VS 5.0%, P < 0.05). The most common adverse event in R group was hiccups. The sedation satisfaction rate and degree of amnesia were higher in the R group (66.7% VS 11.7%) (P < 0.05), and the effect on patient\'s life within 24 hours was lower (12.0% VS 30.5%) (P < 0.05).
UNASSIGNED: The safety and efficacy of remimazolam besylate are not inferior to those of etomidate combined with propofol, rendering it a safe option for sedation during gastrointestinal endoscopy in ASA I-II elderly patients, but care should be taken to monitor the occurrence of hiccups.
摘要：
■雷马唑仑是一种新型的短效苯二氮卓类药物，用于镇静和全身麻醉。本研究旨在评估在接受诊断性胃肠镜检查的老年患者中使用苯磺酸瑞咪唑安定的有效性和安全性。
■将120名年龄在60-75岁的患者随机分为两组。采用瑞芬太尼0.3μg/kg镇痛。患者分别给予苯磺酸瑞米唑仑7mg（R组）或依托咪酯0.1mg/kg联合1%丙泊酚0.5mg/kg（EP组）进行诱导，根据需要给予补充重复剂量。一些时间指标，生命体征,对不良事件进行了评估.比较患者的Mini-cog评分和康复问卷。
■与EP组相比，R组诱导时间稍长(1.50VS1.15分钟)(P<0.05),在麻醉后监护病房（PACU）中花费的时间较短（15.17VS17.40分钟）（P<0.05）。与EP组相比，在T15和T25时间点，R组SBP较低，T2、T3、T5时心率较高(P<0.05)。术后Mini-Cog评分较高(2.83VS2.58)(P<0.05)。EP组呼吸不良事件发生率高于R组(18.3%VS5.0%,P<0.05)。R组最常见的不良事件是打嗝。R组患者的镇静满意率和健忘症程度均较高(66.7%VS11.7%)(P<0.05),对患者24小时内生活的影响较低(12.0%VS30.5%)(P<0.05)。
■苯磺酸瑞马唑仑的安全性和有效性不亚于依托咪酯联合丙泊酚，使其成为ASAI-II老年患者在胃肠内窥镜检查期间镇静的安全选择，但是应该注意监控打嗝的发生。
■将120名年龄在60-75岁的患者随机分为两组。采用瑞芬太尼0.3μg/kg镇痛。患者分别给予苯磺酸瑞米唑仑7mg（R组）或依托咪酯0.1mg/kg联合1%丙泊酚0.5mg/kg（EP组）进行诱导，根据需要给予补充重复剂量。一些时间指标，生命体征,对不良事件进行了评估.比较患者的Mini-cog评分和康复问卷。
■与EP组相比，R组诱导时间稍长(1.50VS1.15分钟)(P<0.05),在麻醉后监护病房（PACU）中花费的时间较短（15.17VS17.40分钟）（P<0.05）。与EP组相比，在T15和T25时间点，R组SBP较低，T2、T3、T5时心率较高(P<0.05)。术后Mini-Cog评分较高(2.83VS2.58)(P<0.05)。EP组呼吸不良事件发生率高于R组(18.3%VS5.0%,P<0.05)。R组最常见的不良事件是打嗝。R组患者的镇静满意率和健忘症程度均较高(66.7%VS11.7%)(P<0.05),对患者24小时内生活的影响较低(12.0%VS30.5%)(P<0.05)。
■苯磺酸瑞马唑仑的安全性和有效性不亚于依托咪酯联合丙泊酚，使其成为ASAI-II老年患者在胃肠内窥镜检查期间镇静的安全选择，但是应该注意监控打嗝的发生。
